CEL-SCI: The Homestretch

|
About: CEL-SCI Corporation (CVM)
by: North Shore Research
This article is exclusive for subscribers.
Summary

Top line results are imminent, and the CEO is still buying stock.

H.C. Wainwright initiates coverage on CEL-SCI to Buy.

The American Cancer Society just published a new report and says oral cancer death rates have increased over the past decade.

We believe that the trial has a high probability of being successful and that the stock is deeply undervalued.

CEL-SCI Corp.'s (NYSEMKT:CVM) Phase III clinical trial of Multikine is about to end soon. We believe, through the due diligence that we have carried out, there is very little risk the primary endpoint